Objective: To evaluate the efficacy and safety of levetiracetam monotherapy or combination therapy for patients with different types of epilepsy ages. Method: A total of 136 patients with epilepsy admited to outpatient the Second Affiliated Hospital of Xi 'an Jiaotong University from Feb. 2010 to Feb. 2012, were treated with levetiracetam, were classified into two groups according to ages. Each group was followed for 1-7 years, observing the therapeutic efficiency and adverse reactions. Results:1. Comparing before and after treatment with LEV, the seizure frequency of each group after treatment decreased significantly. 2. The school-age group had higher rates of response than the infants group. The difference of the efficacy between the two groups was not statistically significant with longer-term follow-up. 3. The response rates of the infants group and the school-age group were 80.8% and 87.1%, respectively.That of the school-age group were 63.6% and 87.5%.4. Comparing between different types of epilepsy, the difference of the efficacy between the two groups was not statistically significant. 5.The major adverse events were sleep increasing, dysphoria, abnormal behavior etc. The incidence of the infants group and the school-age group were 2.8% and 10.8%. Conclusion: Both levetiracetam (LEV) monotherapy or combination therapy for each patients can decrease the seizure frequency of each group after treatment. The difference of the efficacy between different types of epilepsy  was not statistically significant with LEV treatment. The adverse events from LEV has short duration and low incidence.